Innovative Medicines Canada (Medicaments novateurs Canada)
| Specific Topics of Lobbying Communications | Intended Outcomes | Associated Subject Matters |
|---|---|---|
|
Advocate for the adoption of innovative payer agreements at the pan-Canadian level that would incorporate real world evidence
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Advocate for workload capacity building and the acceleration of the work of the pan-Canadian Pharmaceutical Alliance which is an intergovernmental collaboration currently chaired by BC
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Budget 2025 preparation and submission discussion.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Finances and Budgets, Health
|
|
Discussion highlighting the contribution of IMC membership to health outcomes and economic sustainability in British Columbia, and advocating for provincial government policy initiatives and investment decisions (e.g., R&D commercialization incentives, infrastructure support) to support the life sciences sector as a driver of long-term economic growth in the province
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health, Science and Technology
|
|
Discussion on the Pharmaceutical Care Management Strategy
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Engage with the BC government to advocate for greater access to innovative medicines and vaccines for British Columbians, supportive policies to attract research and development investment, and greater collaboration to build a stronger life sciences sector and a more sustainable health system.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
COVID-19, Economic Development and Trade, Finances and Budgets, Government Procurement, Health, Industry
|
|
PharmaCare budget, pharmaceutical listings and the Pharmaceutical Care Management Strategy
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|